Seneca valley virus 3C<sup>pro</sup> substrate optimization yields efficient substrates for use in peptide-prodrug therapy Academic Article uri icon


MeSH Major

  • Cysteine Endopeptidases
  • Picornaviridae
  • Viral Proteins


  • The oncolytic picornavirus Seneca Valley Virus (SVV-001) demonstrates anti-tumor activity in models of small cell lung cancer (SCLC), but may ultimately need to be combined with cytotoxic therapies to improve responses observed in patients. Combining SVV-001 virotherapy with a peptide prodrug activated by the viral protease 3Cpro is a novel strategy that may increase the therapeutic potential of SVV-001. Using recombinant SVV-001 3Cpro, we measured cleavage kinetics of predicted SVV-001 3Cpro substrates. An efficient substrate, L/VP4 (kcat/KM = 1932 ± 183 M(-1)s(-1)), was further optimized by a P2' N→P substitution yielding L/VP4.1 (kcat/KM = 17446 ± 2203 M(-1)s(-1)). We also determined essential substrate amino acids by sequential N-terminal deletion and substitution of amino acids found in other picornavirus genera. A peptide corresponding to the L/VP4.1 substrate was selectively cleaved by SVV-001 3Cpro in vitro and was stable in human plasma. These data define an optimized peptide substrate for SVV-001 3Cpro, with direct implications for anti-cancer therapeutic development.

publication date

  • June 12, 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC4466507

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0129103

PubMed ID

  • 26069962

Additional Document Info

start page

  • e0129103


  • 10


  • 6